MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$51,474K
EPS
-$1.22
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Total revenue
-0 10,000 -
Research and development
34,402 43,027 34,915 33,530
General and administrative
13,178 12,136 12,415 7,454
Acquired in-process research and development
5,000 ---
Total operating expenses
52,580 55,163 47,330 40,984
Loss from operations
-52,580 -55,163 -37,330 -40,984
Other income, net
1,081 2,960 3,552 2,378
Total other income (expense), net
1,081 2,960 3,552 2,378
Loss before income taxes
-51,499 -52,203 -33,778 -
Income tax (provision) benefit
-20 -205 -
Net loss to common stockholders
-51,499 -52,223 -33,573 -38,606
Unrealized gain on investments
35 30 12 -
Foreign currency translation adjustment
-10 -265 -65 -50
Comprehensive loss
-51,474 -52,458 -33,626 -38,656
Earnings per share, basic
-1.22 -1.25 -0.8 -5.02
Earnings per share, diluted
-1.22 -1.25 -0.8 -5.02
Weighted average number of shares outstanding, basic
42,159,340 41,865,400 41,800,802 7,697,695
Weighted average number of shares outstanding, diluted
42,159,340 41,865,400 41,800,802 7,697,695
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$51,474K Unrealized gain oninvestments$35K Foreign currencytranslation adjustment-$10K Net loss to commonstockholders-$51,499K Other income, net$1,081K Loss before incometaxes-$51,499K Total other income(expense), net$1,081K Loss from operations-$52,580K Total operatingexpenses$52,580K Acquired in-processresearch and development$5,000K General andadministrative$13,178K Research and development$34,402K

Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma, Inc. (ZBIO)